Tenaya Share Sales Dilute Column Group Opportunity III's Stake To 21.6%

The fund reported 49,313,559 shares, with warrants covering additional shares excluded because exercise limits applied.

Share
Tenaya Share Sales Dilute Column Group Opportunity III's Stake To 21.6%

Tenaya Therapeutics, which develops treatments targeting the underlying causes of heart disease, diluted The Column Group Opportunity III, LP's stake to 21.6% ownership through additional common-share sales, the shareholder said in an SEC ownership amendment filed Monday. The fund reported 49,313,559 shares held by TCG Opportunity III LP.

More Shares Shrink The Ownership Slice

The ownership calculation used 227,928,240 common shares outstanding on October 29, 2026. Tenaya reported that share count in its quarterly report filed November 4, 2026.

Issuing more stock reduces the percentage represented by an existing holding. The reporting persons attributed this update to Tenaya's additional share sales since their earlier ownership disclosure. They said they had made no transactions in Tenaya securities in the preceding 60 days except those reported in the statement.

The fund also holds warrants covering 35,714,284 shares. Those rights to buy stock were excluded from reported ownership because ownership limits prevented their exercise within 60 days.

Tim Kutzkey and Peter Svennilson, managing members of TCG Opportunity III GP LLC, may share voting and investment authority over the fund's shares. Their ownership reports concern the same securities held by the partnership.

A Heart-Disease Pipeline In Clinical Testing

Tenaya has no products approved for sale. Its lead gene-therapy candidates, TN-201 and TN-401, are in early-to-mid-stage clinical testing.

TN-201 targets hypertrophic cardiomyopathy associated with the MYBPC3 gene. TN-401 targets arrhythmogenic right ventricular cardiomyopathy associated with the PKP2 gene. Another candidate, the small-molecule drug TN-301, has completed early-stage testing in healthy volunteers.

Tenaya plans to commercialize some rare-disease programs itself and seek partners for programs addressing more common conditions. In March 2026, it entered a research collaboration with Alnylam Pharmaceuticals to identify and validate cardiovascular gene targets; Alnylam reimburses certain research costs.

An Established Ownership Reporting History

The fund first reported its Tenaya holding in a passive ownership disclosure on February 11, 2022. It filed its initial Schedule 13D ownership report on December 1, 2022, with subsequent amendments through February 26, 2026.

Monday's update retained the earlier statement of the holding's purpose. The reported stake now represents 21.6% of Tenaya's common-stock class on the SEC beneficial-ownership basis, which includes securities over which reporting persons may exercise voting or investment authority.

Sources

More on Tenaya Therapeutics

All Tenaya Therapeutics (TNYA) coverage →